Immunocore Holdings (IMCR) Invested Capital (2019 - 2026)

Immunocore Holdings has reported Invested Capital for 6 years, with the latest figure at $48.2 million in Q3 2024.

• Quarterly Invested Capital changed N/A year-over-year to $48.2 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $48.2 million (changed N/A YoY) and the FY2022 annual result came in at $160.5 million, up 67.59% from the prior year.
• Invested Capital improved to $48.2 million in Q3 2024 per IMCR's latest filing, from $1.2 million in the prior quarter.
• Over five years, Invested Capital peaked at $160.5 million in Q4 2022 and troughed at $1.2 million in Q2 2023.
• A 5-year average of $70.4 million and a median of $48.4 million in 2020 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2020 and 2021: Invested Capital slumped 41.67% in 2020, then surged 93.9% in 2021.
• Over 5 years, Invested Capital stood at $48.4 million in 2020, then soared by 93.9% to $93.8 million in 2021, then jumped by 71.06% to $160.5 million in 2022, then slumped by 99.23% to $1.2 million in 2023, then soared by 3787.35% to $48.2 million in 2024.
• According to Business Quant data, Invested Capital over the past three periods registered $48.2 million, $1.2 million, and $160.5 million for Q3 2024, Q2 2023, and Q4 2022 respectively.